Investigational drug · Phase 2
OATD-01
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pulmonary Sarcoidosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "OATD-01"
First trial start
2024
Mar 21, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OATD-01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pulmonary Sarcoidosis
Largest trials
Live from ClinicalTrials.gov: studies naming "OATD-01" as an intervention, largest first.
Molecure S.A.Industry
NCT06205121 · 96 participants (planned) · Start Mar 21, 2024 · Primary completion Aug 2027
Drug: OATD-01; Placebo · For: Pulmonary Sarcoidosis
Sites: Birmingham, Alabama; Kansas City, Kansas; Baltimore, Maryland · 28 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Elucidation of the Catalytic Apparatus and Mechanism of Human Chitotriosidaseߛ1.
Niedzialek D, Wieczorek G, Drzewicka K, et al. · ACS Catal 2025
- Correction: Chitinase-1 inhibition attenuates metabolic dysregulation and restores homeostasis in MASH animal models.
· Front Immunol 2025
- Chitinase-1 inhibition attenuates metabolic dysregulation and restores homeostasis in MASH animal models.
Drzewicka K, Guchowska KM, Mlicki M, et al. · Front Immunol 2025
- Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis.
Cha JH, Park NR, Cho SW, et al. · Front Immunol 2024
- Metabolism-driven glycosylation represents therapeutic opportunities in interstitial lung diseases.
Drzewicka K, Zasona Z · Front Immunol 2024
- Inhibition of Macrophage-Specific CHIT1 as an Approach to Treat Airway Remodeling in Severe Asthma.
Sklepkiewicz P, Dymek B, Mlacki M, et al. · Int J Mol Sci 2023
Also in development for Pulmonary Sarcoidosis
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- ATYR1923KRP-R120, EfzofitimodPhase 32 trials
aTyr Pharma, Inc. · Interstitial Lung Disease, Pulmonary Sarcoidosis
- XTMAB-16Phase 23 trials
Xentria, Inc. · Pulmonary Sarcoidosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.